Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 13/20 | 1.00 |
| ▸ | RAF1 | P04049 | 6/20 | 1.00 |
| ▸ | KDR | P35968 | 4/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.56 |
| ▸ | PLK4 | O00444 | 2/20 | 0.56 |
| ▸ | AURKA | O14965 | 2/20 | 0.56 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.56 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.56 |
| ▸ | ABL1 | P00519 | 2/20 | 0.56 |
| ▸ | LCK | P06239 | 2/20 | 0.56 |
| ▸ | FYN | P06241 | 2/20 | 0.56 |
| ▸ | LYN | P07948 | 2/20 | 0.56 |
| ▸ | RET | P07949 | 2/20 | 0.56 |
| ▸ | SRC | P12931 | 2/20 | 0.56 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.56 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.56 |
| ▸ | AXL | P30530 | 2/20 | 0.56 |
| ▸ | FRK | P42685 | 2/20 | 0.56 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.56 |
| ▸ | BLK | P51451 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18809368 | 0.88 | RAF1 (0.78) | EPHX2RAF1KDRMAPK14PLK4 | |
| SCHEMBL257980 | 0.84 | RAF1 (0.82) | EPHX2RAF1KDRMAPK14PLK4 | |
| SCHEMBL1532339 | 0.81 | RAF1 (0.77) | EPHX2RAF1KDRMAPK14PLK4 | |
| SCHEMBL10163311 | 0.80 | RAF1 (0.76) | EPHX2RAF1KDRMAPK14PLK4 | |
| SCHEMBL12391532 | 0.80 | RAF1 (0.76) | EPHX2RAF1KDRMAPK14PLK4 | |
| SCHEMBL12475004 | 0.79 | EPHX2 (0.66) | EPHX2RAF1CA9CA12CA1 | |
| SCHEMBL16620832 | 0.79 | RAF1 (0.74) | EPHX2RAF1KDRMAPK14PLK4 | |
| SCHEMBL19888730 | 0.79 | RAF1 (0.78) | EPHX2RAF1KDRMAPK14PLK4 | |
| SCHEMBL28430251 | 0.79 | RAF1 (0.78) | EPHX2RAF1KDRMAPK14PLK4 | |
| SCHEMBL3653979 | 0.78 | RAF1 (0.69) | EPHX2RAF1KDRMAPK14PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10449182-B2 | Sorafenib derivatives as p21 inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-22 | — | — | US | disclosed |
| EP-2675274-B1 | SORAFENIB DERIVATIVES AS sEH INHIBITORS | UNIV CALIFORNIA (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2675274-B1 | SORAFENIB DERIVATIVES AS sEH INHIBITORS | UNIV CALIFORNIA (US) | 2017-05-03 | — | — | EP | disclosed |
| US-20150132408-A1 | SORAFENIB DERIVATIVES AS P21 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-05-14 | — | — | US | disclosed |
| US-20150132408-A1 | SORAFENIB DERIVATIVES AS P21 INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2015-05-14 | — | — | US | disclosed |
| US-9029401-B2 | Sorafenib derivatives as sEH inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029401-B2 | Sorafenib derivatives as sEH inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-12 | — | — | US | disclosed |
| US-9029401-B2 | Sorafenib derivatives as sEH inhibitors | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-05-12 | — | — | US | disclosed |
| US-20140088156-A1 | SORAFENIB DERIVATIVES AS SEH INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088156-A1 | SORAFENIB DERIVATIVES AS SEH INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-03-27 | — | — | US | disclosed |
| US-20140088156-A1 | SORAFENIB DERIVATIVES AS SEH INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-03-27 | — | — | US | disclosed |
| EP-2675274-A1 | SORAFENIB DERIVATIVES AS sEH INHIBITORS | The Regents of the University of California (US) | 2013-12-25 | — | — | EP | disclosed |
| WO-2012112570-A1 | SORAFENIB DERIVATIVES AS sEH INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088156-A1 | SORAFENIB DERIVATIVES AS SEH INHIBITORS | EPHX1, FAH, EPHX2 | EPHX2 3/4885RAF1 55/4885KDR 53/4885 |
| US-20150132408-A1 | SORAFENIB DERIVATIVES AS P21 INHIBITORS | TP53, CDKN1A, HCCS | EPHX2 2775/4885RAF1 14/4885KDR 611/4885 |
| US-10449182-B2 | Sorafenib derivatives as p21 inhibitors | TP53, CDKN1A, HCCS | EPHX2 2775/4885RAF1 14/4885KDR 611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.